Andrew Bishop

Andrew Bishop

Director of Finance/CFO chez ARCH BIOPARTNERS INC.

Fortune : 792 000 $ au 31/03/2024

58 ans
Finance
Health Technology
Consumer Services

Profil

Andrew Bishop is currently the Chief Financial Officer & Executive Director at Arch Biopartners, Inc. and a Principal at Bingley Capital, Inc. He previously served as an Independent Director at Liminal BioSciences, Inc., Director at Willow Breast & Hereditary Cancer Support, Director at AmacaThera, Inc., Principal at Gordon Capital Corp., Principal at HSBC Securities (Canada), Inc., and Principal at First Marathon Securities Ltd.
Mr. Bishop received his undergraduate degree from McGill University and his MBA from The Schulich School of Business in 1993.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
12/02/2024 480 000 ( 0,76% ) 792 000 $ 31/03/2024

Postes actifs de Andrew Bishop

SociétésPosteDébut
ARCH BIOPARTNERS INC. Director of Finance/CFO 01/04/2010
Private Equity Investor 01/01/2009
Tous les postes actifs de Andrew Bishop

Anciens postes connus de Andrew Bishop

SociétésPosteFin
Director/Board Member -
Willow Breast & Hereditary Cancer Support Chairman -
Gordon Capital Corp. Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -
Voir l'expérience en détail de Andrew Bishop

Formation de Andrew Bishop

McGill University Undergraduate Degree
The Schulich School of Business Masters Business Admin

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Andrew Bishop

Relations

26

Relations au 1er degré

10

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées1
LIMINAL BIOSCIENCES INC.

Health Technology

Entreprise privées7
Gordon Capital Corp.

Finance

Finance

Finance

Arch Biopartners, Inc.

Finance

Willow Breast & Hereditary Cancer Support

Health Technology

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Andrew Bishop